This broad, high-level report analyzes the expanding Personalized Medicine
market. This world market includes important core medical product areas that
will continue to have a powerful impact on current and future healthcare
delivery. This business report examines key market segments such as targeted
drugs and key personalized medicine diagnostics, including companion
diagnostic IVDs, LDTs, diagnostic services and related tools or technologies.
Many people already know about DNA, genes and the human genome. The science
driving personalized medicine includes pharmacogenetics, pharmacoproteomics
and pharmacometabalomix. Personalized medicine uses a targeted drug that
depends on the patient information identified by a companion diagnostic
(genetic biomarker test). The companion diagnostic identifies which patients
would likely benefit from a particular therapy or those who might suffer from
a bad side effect. The test information enables doctors to select the drug
therapy that would benefit the patient. Drug developers in clinical trials
could use a companion diagnostic to select patents that would benefit from a
targeted drug.
The report discusses important technologies, including microarray,
next-generation sequencing, PCR, bioinformatics, nanotechnology and other
platforms. This section highlights key platforms and selected vendors. For
example, the field of clinical next generation sequencing is expected to have
an impact on personalized medicine.
The report covers subjects including important personalized medicine concepts.
The study discusses key biomarkers, commercial diagnostics and therapeutics
that drive personalized medicine. The study highlights new personalized
diagnostics. This research examines the current targeted therapeutics on the
market and drugs in the clinical pipeline.
The report highlights major government regulatory activities that involve
personalized medicine in the US and Europe. The US FDA and the European EMA
have drafted guidance papers to help drug makers and diagnostic firms develop
future targeted therapies guided by companion diagnostics. The recent FDA
approvals of Pfizer's Xalkori for lung cancer and Roche's Zelboraf for
melanoma demonstrate that a surge in new targeted drugs is happening.
Takeda Pacific offers this report in an interactive PDF format. The
interactive feature uses hyperlinks that enable the reader to click the mouse
to jump from Table of Contents items to sections inside the report. The
hyperlinks also allow the reader to click on links to Internet information.
This study discusses important personalized medicine topics and provides the
reader with key findings. The report estimates that the world personalized
medicine market value will reach multi-billions of dollars in 2012, with a
strong double-digit growth rate. This study reviews the activities of 31
companies.
The report uses 71 figures and tables to help the reader scan the details of
major trends, market segmentation, forecast, M&As, partnerships, grant
funding, patents and so on. This must-have report would benefit people with
job titles including CEO, VPs, Director of Business Development, Research
Directors, Entrepreneurs, Venture Capitalists, Investment Planners, Research
Scientists, Consultants or Industry Analysts.
About Takeda Pacific
Analysts at Takeda Pacific developed this report. The company provides
business consulting that focuses on facilitating market research and business
development projects. The business projects may involve European, Japanese
and North American Life Science companies. Since it's founding in late 1992,
TP has reviewed or analyzed thousands of life Science and technology firms for
its clients.
Takeda Pacific has produced numerous industry reports about emerging pharma,
biotech, medical devices and technology companies and markets. The company
also offers follow-up consulting or custom research consulting to assist in
your business development or benchmarking, market assessment projects.
Report Statistics
Publication Date:April 2012
Authors:Jay K. Myers, Paula Mitchell Myers
Total Number of Pages:171(can be printed; fully searchable PDF
format)
Figure 6. Biopsy Tissue Diagnostics using Quantum Dot Technology
Figure 7. WW Total Core Personalized Medicine Market Size ($M), 2011-2016
Figure 8. WW Personalized Medicine Therapeutic Product Market Size ($M)
Figure 9. WW Personalized Medicine Therapeutic Market Size by Major Disease
Figure 10. WW Personalized Medicine Therapeutic Market Size by Region
Figure 11. Personalized Medicine Diagnostic Product Market Size by
Technology
Figure 12. WW Personalized Medicine Diagnostic IVD Market By Major Disease
Figure 13. WW Companion Diagnostic IVD Test & LDT Service Market
Figure 14. WW Companion Diagnostic IVD & LDT Lab Services Market by Major
Disease
Figure 15. Personalized Medicine Diagnostic IVD Market by WW Regions
Figure 16. WW Personalized Medicine Diagnostic Lab Services By Major
Disease
Figure 17. WW Personalized Medicine Diagnostic Lab Service Market by
Regions
Personalized Medicine: Companies, Trends and World Market published by Takeda Pacific in April 23, 2012. This report consists of 171 Pages and the price starts from US $ 2495.
Press Release
FDA Approval of Roche's Zelboraf and Pfizer's Xalkori Indicate Rise of Targeted Drugs
May 7th, 2012
Global Information Inc. would like to present a new market research report, "Personalized Medicine: Companies, Trends and World Market" by Takeda Pacific.
Recent FDA approvals of Pfizers Xalkori for lung cancer and Roches Zelboraf for melanoma demonstrate that a surge in new targeted drugs is underway. According to Takeda Pacific, the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have drafted guidance papers to help drug makers and diagnostics firms develop future targeted therapies guided by companion diagnostics. The new report from Takeda Pacific highlights major government regulatory activities surrounding personalized medicine in both the U.S. and Europe.
The Personalized Medicine market includes significant core medical product areas that will continue to have a powerful impact on current and future healthcare delivery. The science driving personalized medicine includes pharmacogenetics, pharmacogenproteomics and pharmacometabalomix. Personalized medicine uses a targeted drug that depends on the patient information identified by a companion diagnostic (genetic biomarker test).
This report examines key market segments such as targeted drugs and key personalized medicine diagnostics, including companion diagnostic IVDs, LDTs, diagnostic services and related tools or technologies. Important technologies examined include: microarray, next-generation sequencing, polymerase chain reaction (PCR), bioinformatics, nanotechnology and other platforms. The report highlights new personalized diagnostics and also covers key biomarkers, commercial diagnostics and therapeutics that drive personalized medicine.
